2nd Quarter 2008
View Covance's Webcast, "The Role of Observational Studies in Demonstrating Product Value," on demand until June 19th!
Payers, providers, policymakers, and manufacturers are increasingly relying on the use of evidence-based data to evaluate the role of innovative therapies relative to current standard-of-care practices. Manufacturers frequently include outcomes-based endpoints in investigational trials, but the traditional randomized clinical trial often has limited generalizability to routine clinical practice.
Covance Market Access Services invites you to view this Webcast on demand to learn how observational studies are commonly used to demonstrate product value in real world populations during introduction into the marketplace and at various times during the post-approval product life cycle.
What are the strengths and limitations of observational studies?
Find out from Thomas Goss, PharmD, a Covance vice president, in this informative one-hour Webcast that you can watch anytime from now until June 19th.
Watch now.
In this Webcast, Covance's pharmacoeconomics and outcomes expert discusses how to
- successfully integrate pharmacoeconomics and clinical objectives in observational studies,
- target patient-reported outcomes and economic endpoints to document burden of illness associated with routine clinical practice and define unmet medical need using empirical observational data, and
- support value statements associated with a new therapy using observational data.
Watch now to learn more.
| Who should watch: |
Health economic and outcomes, marketing, medical affairs, and pharmacovigilance/safety groups at pharmaceutical or biotechnology companies |
| Presenter: |
Thomas Goss, PharmD, Vice President |
| Cost: |
Complimentary |
Watch now!
|
